Drugs / 18F-TRX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06942104 | Jul 2025 → Sep 2026 overdue | castration-resistant prostate carcinoma, clear cell renal carcinoma, malignant glioma, metastatic malignant neoplasm | Rahul Aggarwal | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-TRX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06942104 ↗ |
| Modality | Diagnostic / imaging agent | “18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.” NCT06942104 ↗ |
| Route | Intravenous | “Given Intravenously (IV)” NCT06942104 ↗ |